ANIP.OQ
Latest Trade
72.39USDChange
--(--)Today's Range
-
--52 Week Range
-
86.67As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 72.39 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 3.25 |
Today's High | -- |
Today's Low | -- |
52 Week High | 86.67 |
52 Week Low | 39.83 |
Shares Out (MIL) | 12.10 |
Market Cap (MIL) | 859.62 |
Forward P/E | 12.41 |
Dividend (Yield %) | -- |
Ani Announces Positive Clinical Results From Cortrophin Gel Cortisol Response Study
ANI Pharmaceuticals Reports Q2 GAAP Earnings Per Share $0.53
ANI Pharmaceuticals Expands Generic Pipeline With Acquisition Of Seven Development Stage Drug Products From Coeptis Pharmaceuticals
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Industry
Biotechnology & Drugs
Executive Leadership
Robert E. Brown
Independent Chairman of the Board
Arthur S. Przybyl
President, Chief Executive Officer, Director
Stephen P. Carey
Chief Financial Officer, Vice President - Finance
Robert W. Schrepfer
Senior Vice President -New Business Development and Specialty Sales
James G. Marken
Senior Vice President-Operations and Product Development
Price To Earnings (TTM) | 49.21 |
|---|---|
Price To Sales (TTM) | 4.00 |
Price To Book (MRQ) | 4.14 |
Price To Cash Flow (TTM) | 14.22 |
Total Debt To Equity (MRQ) | 89.42 |
LT Debt To Equity (MRQ) | 31.63 |
Return on Investment (TTM) | 5.27 |
Return on Equity (TTM) | 4.02 |
* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS AND REAFFIRMS GUIDANCE
* ANI PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE GENERIC PRODUCTS AND ASSETS FROM AMNEAL/IMPAX
* ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION
ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single :
* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC
* ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE
* ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK
* ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION
* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance
* ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml
* Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance
* Ani Pharmaceuticals Inc - announced launch of diphenoxylate hcl and atropine sulfate tablets, 2.5mg/0.025mg Source text for Eikon: Further company coverage:
* Files for mixed shelf of up to $350.0 million Source text: (http://bit.ly/2rokUdK) Further company coverage:
* Ani pharmaceuticals inc - launch of pindolol tablets, 5mg and 10mg, which is used in treatment of hypertension Source text for Eikon: Further company coverage:
* Ani Pharmaceuticals reports first quarter results and year-to-date 2017 highlights and reaffirms guidance
* ANI Pharmaceuticals -launch of Indapamide tablets, 1.25mg and 2.5mg, used in treatment of hypertension & swelling associated with congestive heart failure Source text for Eikon: Further company coverage:
* Ani pharmaceuticals reports full year 2016 results and fourth quarter results and provides 2017 guidance
* Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt
* Ani Pharmaceuticals Inc - in consideration for acquisition of Cranford assets, company paid a purchase price of approximately $20 million - SEC filing
* ANI Pharmaceuticals reports record third quarter results and year-to-date 2016 highlights and narrows full-year guidance
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.